Trial Profile
A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2024
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Prostate cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 25 Oct 2023 Planned End Date changed from 1 Dec 2025 to 30 Jun 2026.
- 25 Oct 2023 Planned primary completion date changed from 1 Dec 2025 to 30 Jun 2026.
- 17 Nov 2021 Planned End Date changed from 13 Feb 2024 to 1 Dec 2025.